Comparative Study Between 2% Minoxidil Topical Spray vs. Intradermal Injection for Treatment of Androgenetic Alopecia in Female Patients: A Controlled, 4-Month Randomized Trial

A 35-year-old male uses topical minoxidil, spironolactone, and microneedling for hair loss, with spironolactone prescribed based on a DNA test indicating poor response to finasteride and dutasteride. Despite concerns about the test's validity and spironolactone's side effects, he reports stable or improved hair condition and no low testosterone symptoms.

Minoxidil may inhibit androgen receptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.

Mesotherapy with vitamins is unlikely to effectively treat genetic hair loss and may be a waste of money. Taking 0.25 mg of finasteride daily is likely sufficient to slow hair loss, as it provides similar benefits to higher doses with fewer side effects.

Topical minoxidil is effective for hair loss, while topical finasteride caused side effects like erectile dysfunction. Mesotherapy is considered stronger than home treatments like microneedling with topical nutrients.

The user stopped oral treatments due to side effects and switched to a regimen of topical minoxidil, tretinoin, azelaic acid, and dermaneedling, with recent addition of topical finasteride. They are questioning the long-term effectiveness of non-hormonal methods and considering hair transplantation.

Minoxidil was applied to a single miniaturized hair follicle over four months, resulting in less miniaturization but not yet terminal growth. The user used a 5% minoxidil solution, specifically the Regaine brand, and observed changes using a handheld WiFi microscope.